Depot injection

A depot injection leaves a slow-release reservoir of drug under the skin or in muscle, where the formulation releases its payload into the blood over days or weeks. The depot meaning is literal: medicine is parked at the injection site instead of entering circulation all at once, so doses can be spaced farther apart.

How does a depot injection work?

A depot injection slows the step between injection and absorption. The drug may sit in oil, form a poorly soluble deposit, or be trapped inside biodegradable particles. Water enters, drug diffuses out, or the carrier breaks down. The precise release clock belongs to the finished formulation; “depot” does not describe one universal ingredient or one fixed number of days.

The NCBI Bookshelf definition describes depot medicines as injections placed under the skin or in muscle that release their active ingredient gradually. Picture a sprinkler tank with a narrow outlet. The whole load arrives at the site on day one, but only a fraction reaches the bloodstream at a time.

That reservoir is the important part. A regular water-based injection can be absorbed fairly quickly. An extended release injection deliberately makes absorption the bottleneck, using the formulation to meter out the same active drug more slowly. “Slow release peptide” on a product listing is not enough to establish a depot, though; the carrier, release data, and tested route still need to exist.

Why is extended-release exenatide weekly?

Extended-release exenatide is weekly because the peptide is sealed inside biodegradable polymer microspheres that remain under the skin and release drug in stages. Immediate-release exenatide is the same active peptide without that depot system and was designed for twice-daily dosing. The longer schedule comes from delivery engineering, not a different GLP-1 receptor effect.

The DailyMed label identifies Bydureon BCise as exenatide extended-release microspheres suspended in a medium-chain-triglyceride vehicle. The microspheres use poly(lactide-co-glycolide), usually shortened to PLG or PLGA. After injection, the particles hydrate. Some exenatide near the surface escapes first; deeper drug diffuses out later; fully enclosed drug appears as the polymer breaks down.

The human pharmacology paper found that less than 1% of the exenatide was loosely bound at the surface, while later release phases peaked around two weeks and seven weeks. Weekly injections therefore overlap. A seven-day dosing interval does not mean the previous depot turns off on day seven; several small reservoirs are releasing at once as concentrations build toward a steady level.

Is a depot the same as a long half-life?

A depot can produce long action without giving the free peptide a long intrinsic half-life. The reservoir controls how quickly drug enters the blood; once a released molecule is circulating, the body may clear that molecule at its usual rate. Release time and clearance time sit on different sides of the pharmacokinetic ledger.

Exenatide makes the distinction unusually clean. Immediate-release exenatide has a reported plasma half-life of about 2.4 hours, yet the microsphere version supports weekly dosing because fresh exenatide keeps leaving the injection site. Calling every depot drug “a peptide with a week-long half-life” would confuse a slow feed into blood with slow removal from blood.

How is a depot different from lipidation or DAC?

A depot holds drug at the injection site; lipidation and a drug affinity complex (DAC) are albumin-binding strategies that help a peptide stay in circulation after absorption. The mechanisms start in different places but chase the same practical goal: useful exposure for longer, with fewer injections. One slows entry. The others slow clearance.

Lipidation adds a fatty chemical group that can bind albumin reversibly. A drug affinity complex uses a reactive chemical handle to attach a peptide to albumin. Neither term is a synonym for depot injection. A molecule can be engineered for albumin binding without leaving a slow-release reservoir at the needle site, and a polymer depot can work without changing the peptide molecule at all.

This distinction matters when comparing weekly peptides. Two products can share a seven-day schedule while arriving there by completely different pharmacology. Frequency alone does not reveal the mechanism.

Does a depot have to be injected into muscle?

A depot does not have to be intramuscular. Some products form reservoirs in muscle, while extended-release exenatide forms its microsphere depot after a subcutaneous injection. Route and release design are separate facts, and the tested route for the exact product decides where the formulation belongs.

The subcutaneous-versus-intramuscular guide explains the tissue difference. Moving a formulation from under the skin into muscle can change blood flow, local tolerability, and absorption. “Depot” is therefore not permission to choose the deeper route. The current Bydureon BCise label specifies subcutaneous use and explicitly says not to inject the product into muscle or a vein.

What does the evidence actually establish?

Depot evidence has layers: a label can verify composition and route, pharmacokinetic studies can measure the release curve in people, and outcome trials can test whether the medicine treats a condition. One layer cannot quietly stand in for the next. A clever reservoir proves controlled delivery only when release has actually been measured.

For exenatide, the evidence is strong at each relevant layer. DailyMed documents the labeled formulation and weekly route; human studies measured the staged release and blood concentrations; diabetes trials established clinical effects for the finished medicine. Those facts do not validate an unrelated research vial advertised as a slow release peptide. Without a named carrier and human release data, “extended release” remains a claim on a label, not a demonstrated depot.

That is the useful test: ask what stays at the injection site, how it releases, which route was studied, and whether the evidence measures delivery or a health outcome. The peptide glossary can decode the other terms; the reservoir itself is what makes a depot a depot.